IBC Life Sciences
The leading provider of scientific, technological and business information
Main menu
My IBC
ACT 2009: Cellular and Physiologically Relevant Models for Lead Discovery and Profiling
CSS
Event Information
Document Title
Event Overview
We've changed the format for this year's ACT: Cellular & Systems Models for Human Disease Biology conference.
Feedback about the program has been extremely positive, but scheduling and travel restrictions are making it hard for many to attend. We've gotten so many requests for online access to the content that we've decided to go virtual!
The ACT program is now called Cellular and Physiologically Relevant Models for Lead Discovery and Profiling and will be available exclusively online. The online conference programming will consist of selected end-user and case study presentations given in a combination of live and on-demand web formats.
The live component of the online program will take place December 10. All presentations thereafter will be archived.
The webinar is free of charge. All attendees must pre-register online to gain access to both the live and archived presentations.
| Supporters |
 |
LIVE WEBINAR PRESENTATIONS
The following 3 presentations will be broadcasted live on December 10th followed by a question and answer session with the presenters. After December 10th, they will be archived and will be available to view on-demand until January 10th, 2010.
Unpublished New Data
This talk will explore the pros and cons of screening relevant cellular models based on examples of actual projects. Challenges both in the screens and bringing the chemical output to Lead and Candidate will be discussed. Examples will be drawn from diverse therapeutic indications.
Tina Garyantes, Ph.D., Senior Director, Global Head of Screening and Assay Sciences, Sanofi-Aventis
Unpublished New Data
Study
High-throughput phenotypic screening of relevant cell types shows great potential for screening compounds in an information-rich way. We describe a high-content HTS measuring differentiation of rat glial precursor cells from a simple morphology towards a complex oligodendrocyte phenotype. Progressive algorithm refinement and multi-parametric analyses permitted the analysis of a large number of compounds. Bioinformatics and cheminformatics were utilized to annotate and expand upon several series identified.
Jane Peppard, Ph.D., Lead Research Investigator, Screening and Assay Sciences, Sanofi-Aventis
Pilot Study with Patient Samples
Several publications have demonstrated the predictive value of cell-based in vitro toxicology assays. We have developed a high-content, multiparameter imaging cytotoxicity assay and will present data to illustrate the value of this assay for the prediction of rodent and human toxicity and for the optimization of drug discovery compounds.
Lore Gruenbaum, Ph.D., Senior Principal Scientist, Integrative Biology, Boehringer Ingelheim Pharmaceuticals, Inc.
PRE-RECORDED WEBINAR PRESENTATIONS
Available to view on-demand from December 10th, 2009 to January 10th, 2010
Bruce R. Conklin, M.D., Senior Investigator, Gladstone Institute of Cardiovascular Disease
Unpublished New Data
The search for therapeutic synergy of anti-cancer compounds has always been a significant effort in the area of Oncology research. Knowledge of effective synergy with associated specific genotyping would help guide the selection of the most effective drug combinations for patient subgroups, as well as lead to identification of corresponding genetic response signatures. Unfortunately, testing drug combinations in animals is labor intensive and does not provide sufficient dynamic range or genotypic diversity. In this presentation, we will discuss the experimental design, execution flow, data analysis and results for testing drug combinations, using a high-throughput cell-based assay system.
Adrie Jones, Senior Associate Scientist, Amgen, Inc.
Unpublished New Data
At their heart, autoimmune processes are a dysfunction of the immune system manifested by cell type specific pathology. We present a global profile of the network of immune cell interactions determined at the single cell level as a function of cytokine-cell type-signaling pathway action (nodes) in normal and RA individuals. Viewed in this manner, we can extract a remarkable number of clinical and drug use predictive node correlates, as well as a systems biology view of key nodes that are re-routed in RA, suggesting both the mechanism of RA diseases processes as well as novel opportunities for drug development.
Jason Ptacek, Ph.D., Postdoctoral Fellow, Garry P. Nolan Laboratory, Stanford University School of Medicine
Study
SGI-1252 is a novel JAK2 inhibitor with potent in vitro and in vivo activity against JAK2-dependent pharmacodynamic endpoints. To further characterize SGI-1252 as a JAK2 inhibitor, we screened it against 20 cell lines engineered to evaluate a compound's activity against multiple signaling pathways. Results from this screen suggest that SGI-1252 is highly selective for pathways that involve JAK2 signaling and has minimal activity against other pathways included in the screen.
Jason Foulks, Ph.D., Scientist I, Assay Development, SuperGen, Inc.
Bottom menu
Copyright IBC Life Sciences, a part of Informa Life Sciences Group. | Phone: 800.390.4078 | Email: reg@ibcusa.com